

*Evaluation of Clinical Prognostic Factors of Diffuse
Large B-Cell Lymphoma (DLBCL) as Regards
Treatment Outcome with CHOP Regimen-
Retrospective Analysis (1998 -2006)*

Thesis

Submitted for fulfillment of master degree (M.Sc.)

In internal medicine

By

Marwa Nagi Mehesen

Supervised by

Prof. Dr. Mona El Kassas

Professor of internal Medicine

Faculty of Medicine, Cairo University

Dr. Thoraya Abd El Hamed

Assistant Professor of Medical oncology

National Cancer Institute, Cairo University

Dr. Mohamed Abd El Mooti

Lecturer of Medical Oncology

National Cancer Institute, Cairo University

Faculty of Medicine
Cairo University
2006

Abstract


The aim of this retrospective study is to determine the efficacy, outcome and feasibility of standard CHOP regimen as a first line treatment to DLBCL using clinical risk stratification models such as International prognostic index (IPI) , patients profile and dose intensity of cyclophosphamide and adriamycin as effective tools for predicting outcome of the patients with lymphoma.

The study includes two hundreds and twenty four patients with diffuse large B cell lymphoma who were treated with 3 to 8 cycles standard CHOP regimen during the period between 1998 and 2006. One hundred and seventy eight patients (79.5%) achieved CR after CHOP regimen with an observation period of 51 months.

Key Words :

Autologous Stem Cell Transplant – Clinical staging – Dose intensity .

ACKNOWLEDGEMENT



I am immensely and deeply grateful to **Prof. Dr. Mona El-Kassas** Professor of Internal Medicine, Faculty of Medicine, Cairo University, for her sincere guidance, supervision and continuous noble-minded encouragement.

I am greatly indebted and much grateful to **Dr. Thorayaa Abd el Hamed** Assistant Professor of Medical oncology, National Cancer Institute, Cairo University, for her huge assistance and sincere help.

I would like to express my profound gratitude to **Dr Mohamed Abd el Mooti** Lecturer of Medical oncology, National Cancer Institute, Cairo University, for without his untiring guidance and faithful efforts, this work would never have been completed.

I wish to extend my cordial thanks to **Prof. Dr. Nelly Hassan Alieldin** Professor of Epidemiology & Biostatistics, National cancer institute, Cairo University, for his great help in the statistical part of this work.

Marwa Nagi

**To My Family and My parents
For Their everlasting love,
encouragement & sacrifices**

INDEX

	Page
CONTENT	i
LIST OF ABBREVIATIONS.....	iii
LIST OF TABLES.....	vi
LIST OF FIGURES.....	x

CONTENT

	Page
Introduction And AIM of work	1
Review Of Literature	4
* Epidemiology of NHL	4
* Etiology of NHL	6
* Classification of NHL.....	8
* Pathology of DLBCL.....	14
- Morphology	14
- Pathological classification.....	15
- Molecular pathogenesis of DLBCL	16
* Diagnosis of NHL.....	27
* Staging of NHL.....	29
* Prognostic factors of NHL.....	32
* Treatment of diffuse large B cell lymphoma.....	38
- Therapy of localized large B-cell lymphoma	40
- Therapy of disseminated diffuse large B. cell lymphoma.....	44
- Salvage Therapy	58
* Radiation therapy in the treatment of large cell lymphoma	62
PATIENTS AND METHODS.....	64
RESULTS	71
DISCUSSION.....	101
SUMMARY	109

REFFRENCES	112
ARABIC SUMMARY	

LIST OF ABBREVIATIONS

ABC-DLBCL	: Activated B cell-Like Diffuse Large B cell lymphoma
aaIPI	: age adjusted international prognostic index.
ABC	: Activated Like B cell lymphoma
ACVBP	: Doxorubicin;Cyclophosphamide;Vindesine;Bleomycin; and Prednisone .
ASCT	: Autologus stem cell transplant
CD	: Cluster of differentiation
CEPP-B	: Cyclophosphamide; Etoposide; Prednisone; Procarbazine; and Bleomycin.
CHOP	: Cyclophosphamide;Doxorubicin;Vincristine;and Prednisone
CHOEP	: Cyclophosphamide;Hydroxydaunorubicin;Oncovin; Etoposide; and Prednisone
R-CHOP	: Rituximab,Cyclophosphamide;Doxorubicin;Vincristine;and Prednisone
CNS	: central nervous system
CR	: Complete remission
CS	: Clinical staging.
CSF	: cerebrospinal fluid
CT	: computed tomography scans.
DFS	: Disease free survival
DI	: Dose intensity
DLBCL	: Diffuse large B cell lymphoma.
DNA	: Deoxy ribose nucleic acid
EBV	: Epstein-Barr virus
ECOG	: Eastern – Cooperative Oncology Group.
EPOCH	: Cyclophosphamide;Hydroxydaunorubicin;Oncovin; Etoposide; and Prednisone
ESHAP	: Etoposide; Methyleprednisone; cisplatin; and Cytarabine.

EVA	: Etoposide; Vinblastine; Adriamycin.
FDA	: Food & Drug Administration
FDG	: 2-Fluoro-2- deoxy-d-glucose
FL	: Follicular lymphoma
Fig	: Figure
G-CSF	: Granulocyte colony–stimulating factor
GC	: Germinal center
GELA	: Groupe d'Etude des Lymphomes de l'Adulte
HCV	: Hepatitis C virus
HD	: Hodgkin's disease
HDT	: High dose therapy
HIV	: Human immunodeficiency virus
HLA	: Human leucocytic antigen.
HTLV-1	: Human T cell lymphotropic virus type 1
IF	: Involved field
Ig	: Immunoglobuline
INPI project	: International Non Hodgkin's lymphoma prognostic factors project.
IPI	: International prognostic Index
IPT	: Immunophenotyping
leu	: Leucyte
LDH	: Lactate dehydrogenase
MALT	: Mucosa associated lymphoid tissue
M-BACOD	: Methotrexate;Bleomycin;Adriamycin;Cyclophosphamide; Oncovin; and Dexamethasone
MACOP-B	: Methotrexate; Adriamycin;Cyclophosphamide; Oncovin; and Bleomycin
Min T trial	: Mab Thera International trial
MRI	: Magnetic Resonance Imaging
MTD	: Maximum tolerated dose
NCI	: National cancer institute
N-GC	: Non Germinal center
NHL	: Non Hodgkin's lymphoma.

N-HLPC	:	Non Hodgkin's lymphoma pathological classification project.
NK	:	Natural killer cells.
No.	:	Number
OR	:	overall response
OS	:	Overall Survival
PCR	:	Polymerase chain reaction.
PD	:	Progressive disease
PET	:	Position emission tomography
PR	:	Partial remission
Pro-MACE- CytaBOM	:	Prednisone; Adriamycin; Cyclophosphamide; Etoposide; Cytarabine; Bleomycin; Oncovin; and Methotrexate
PS	:	Pathological staging
PS	:	Performance status
Pt.	:	Patient
RDI	:	Relative dose intensity
REAL	:	Revised European-American lymphoma.
RT	:	Radiotherapy
SD	:	Stable disease
SHM	:	Somatic hypermutation
SWOG	:	South-West Oncology Group
TdT	:	Terminal deoxynucleotidyl Transferase.
TTF	:	Time-to-treatment failure
V-Region	:	Variable region
Vs.	:	Versus
WF	:	Working Formulation
WHO	:	World Health organization

LIST OF TABLES

	Page
Table (1) Statistical Data from the department of pathology registry, NCI during the period 1998-2000.....	4
Table (2) The possible etiological and risk factors which may be associated with development of NHL	7
Table (3) Modified Rappaport classification.....	9
Table (4) Kiel classification	9
Table (5) Working Formulation for clinical usage	11
Table (6) Updated REAL/WHO Classification of lymphoid neoplasm	12
Table (7) DLBCL morphological variants.....	14
Table (8) DLBCL in NHL classification systems	15
Table (9) Initial screening panel for unclassified malignant neoplasms.....	15
Table (10) Chromosomal translocations in NHL.....	20
Table (11) Major recurring genetic events in DLBCL	24
Table (12) The Ann Arbor staging system and Cotswold Modifications.....	31
Table (13) International Prognostic Index	33
Table (14) Outcome of Aggressive Non Hodgkin's lymphoma according to IPI score.....	34

	Page
Table (15) Tissue microarray criteria for germinal center B-cell (GCB) versus nonGCB derivation of diffuse large B cell lymphoma(DLBCL)	37
Table (16) Common chemotherapeutic regimens used in treatment of DLBCL	39
Table (17) chemotherapy versus combined modality therapy for stage I/II intermediate-or High-Grade Lymphoma: prospective randomized trials	41
Table (18) Treatment of Aggressive Non-Hodgkin's Lymphoma (Approximately 80% Diffuse Large B cell): A Comparison of Four Regimens.....	45
Table (19) Randomized trials of induction therapy followed by HDT/ASCT consolidation in newly diagnosed previously untreated aggressive lymphomas	57
Table (20) Salvage Regimen for Hodgkin and non Hodgkin Lymphoma.....	61
Table (21) standard CHOP Regimen (every 21 days)	67
Table (22) Assessment of treatment response	69
Table (23) age adjusted International Prognostic Index (aa IPI).....	70
Table (24) Characteristics of 224 patients with DLBCL who had received standard CHOP regimen.....	73
Table (25) Extranodal involvement in the whole group of patients (224 patients)	77

	Page
Table (26) Summary of calculated dose intensity and relative dose intensity of adriamycin and cyclophosphamide in 224 patients with DLBCL.....	79
Table (27) Correlation of aa IPI and its factors with the CR rate in the 224 patients who had received standard CHOP	84
Table (28) Correlation of aa IPI and its factors with the OS rate in the 224 patients who had received CHOP regimen.....	85
Table (29) Correlation of aaIPI and its elements with the DFS In 178 patients who entered in CR	86
Table (30) Correlation of Extranodal involvement with the CR rate in 224 patients who had received CHOP regimen.....	87
Table (31) Correlation of Extranodal involvement with the OS rate in 224 patients who had received CHOP regimen.....	87
Table (32) Correlation of the tumor Bulky to the CR and OS rate in patients who had received CHOP regimen.....	88
Table (33) Correlation of dose intensity & relative dose intensity of adriamycin and cyclophosphamide with CR and OS rate in patients who had received CHOP regimen.....	94
Table (34) Correlation of dose intensity & relative dose intensity of adriamycin and cyclophosphamide to DFS in patients who had entered in CR.....	95

	Page
Table (35) Significant, independent prognostic factors found to affect response to chemotherapy by logistic regression in 224 patients.....	99
Table (36) Significant, independent prognostic factors found to affect overall survival by logistic regression in 224 patients.....	100

LIST OF FIGURES

	Page
Fig.1	Frequency of Lymphoma in Arab word5
Fig.2	schema used for differentiation of DLBCL36
Fig.3	Tumor cytoreduction and regrowth after conventional, dose escalated and dose ense chemotherapy.....50
Fig.4	Sex distribution of 224 patients with DLBCL who had received standard CHOP regimen.....74
Fig.5	performance status of 224 patients with DLBCL who had received standard CHOP regimen74
Fig.6	Stage characteristics of 224 patients with DLBCL who had received standard CHOP regimen75
Fig.7	B symptoms of 224 patients with DLBCL who had received standard CHOP regimen.....75
Fig.8	LDH level of 224 patients with DLBCL who had received standard CHOP regimen.....76
Fig.9	Age-adjusted IPI of 224 patients with DLBCL who had received standard CHOP regimen76
Fig.10	Overall survival in 224 patients who had received standard CHOP regimen81
Fig.11	Disease free survival rate in 224 patients who had received standard CHOP regimen.....81
Fig.12	correlation of age-adjusted IPI in 224 patients who had received standard CHOP regimen with OS89